Company Overview

Statera Biopharma, Inc. (NASDAQ previously: STAB) was a clinical-stage biopharmaceutical company focused on the development of immunotherapy and immune restoration technologies for autoimmune diseases and cancer. Public filings and historical investor materials describe the company as operating within the biotechnology and biopharmaceutical industries, with a primary emphasis on therapies designed to modulate immune system responses through cytokine-based and immunomodulatory approaches.

The company evolved through a series of restructurings and strategic transitions, including operating previously under the name Cytocom, Inc. before rebranding as Statera Biopharma. Its business model centered on research and development rather than commercial product sales, meaning its primary financial activity historically came from capital raising, licensing activity, and strategic transactions rather than recurring operating revenue. Public disclosures indicate the company sought differentiation through platform-based immunology programs targeting both inflammatory and oncology indications. Data regarding later-stage commercialization progress and long-term operating continuity is inconclusive based on available public sources.

Business Operations

Statera Biopharma’s operations were primarily organized around clinical and preclinical biotechnology development programs rather than diversified commercial business segments. Historical filings reference immune modulation assets and therapeutic candidates intended for oncology and autoimmune applications. The company’s activities included drug development, regulatory planning, intellectual property management, and clinical research coordination. Because the company remained in the development stage, revenue generation was limited and largely dependent on financing activities, licensing arrangements, and strategic partnerships.

The company’s operational footprint appeared concentrated in the United States, with research collaborations and external development relationships supporting its pipeline activities. Publicly available disclosures indicate the company relied on outsourced clinical development infrastructure and third-party manufacturing relationships typical of smaller biotechnology firms. Information regarding active joint ventures, material international subsidiaries, or durable commercial partnerships is limited in publicly available filings, and some operational details remain inconclusive due to the company’s limited scale and evolving corporate structure.

Strategic Position & Investments

Statera Biopharma’s strategic direction focused on advancing immune-focused therapeutic candidates through clinical development while seeking external capital and partnership opportunities. Company materials emphasized immunotherapy as a long-term growth area, particularly therapies intended to rebalance immune response mechanisms in cancer and inflammatory diseases. Its strategy also included evaluating acquisitions, licensing opportunities, and portfolio expansion initiatives intended to strengthen its biotechnology pipeline.

Historical disclosures indicate the company pursued intellectual property development and targeted investments in cytokine and immune-regulation technologies. However, compared with larger biotechnology companies, Statera Biopharma operated with limited financial resources and faced the risks typical of small-cap clinical-stage biotechnology firms, including regulatory uncertainty, development funding needs, and commercialization challenges. Public records do not clearly establish a broad portfolio of operating subsidiaries or significant equity investments in external companies.

Geographic Footprint

Statera Biopharma’s principal operations were centered in the United States, where the company maintained its corporate and development activities. Its business activity was primarily tied to the North American biotechnology ecosystem, including U.S.-based clinical development, regulatory engagement, and investor relations functions. Public filings indicate that the company’s operational influence outside the United States was limited compared with multinational pharmaceutical organizations.

Although biotechnology development frequently involves international research vendors and contract organizations, publicly available information does not indicate that Statera Biopharma maintained major standalone operational hubs across Europe, Asia-Pacific, or other global regions. Its international exposure appeared to be indirect and partnership-driven rather than based on substantial foreign infrastructure or broad commercial distribution networks.

Leadership & Governance

Statera Biopharma was governed through a traditional public-company structure consisting of executive leadership and a board of directors. The company’s strategic focus, based on public communications and filings, emphasized advancing immunotherapy programs, securing financing, and positioning the organization for clinical development progression. Due to changes in management and corporate activity over time, some executive role timelines vary across filings.

Key executives identified in historical public disclosures include:

• Michael K. Handley – Chief Executive Officer
• Gregory A. Mayes – Chief Financial Officer
• Dennis M. Mangan, Ph.D. – Chief Scientific Officer

Public filings, including historical SEC filings, indicate that leadership emphasized scientific advancement, clinical development execution, and capital market access as central components of the company’s operating strategy. Certain governance and executive details may have changed over time, and some information is inconclusive based on the latest publicly available disclosures.